ARTV (Artiva Biotherapeutics) שווי החברה בספרים

Artiva Biotherapeutics, Inc. (ARTV) management focuses on developing cutting-edge cell therapy methods, successfully raising capital for early-stage production. The historical price action shown below correlates with the 0.35 metric. The business model relies on outsourcing drug manufacturing in Asia while retaining exclusive rights to the developments. Transparent cooperation with GC Cell and the top management's experience in bringing NK products to market ensure quality control following the IPO.

To identify fundamental stability drivers, an investor must evaluate the difference between total assets and liabilities, which allows for the real-time tracking of the enterprise's actual asset value. The trend of net balance sheet assets for Artiva Biotherapeutics, Inc. (ARTV) on the GURU.Markets platform confirms the financial resilience of Artiva Biotherapeutics, Inc. (ARTV), reflecting the capitalization of resources required to maintain the closed-loop production cycle of AlloNK cell therapy and to fulfill exclusive contracts with pharmaceutical behemoths.